Interleukin-1β induces a reversible cardiomyopathy in the mouse

Inflammation Research

Volumn 62, Issue 7, 2013, Pages 637-640

  Van Tassell, Benjamin W ^a,b,c   Seropian, Ignacio M ^a,b   Toldo, Stefano ^b,c   Mezzaroma, Eleonora ^a,b   Abbate, Antonio ^b,c  

^a Pharmacotherapy and Outcome Sciences   (United States)

^b JOHNSON RESEARCH   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cardiomyopathy; Contractility; Heart failure; Interleukin 1

Indexed keywords

INTERLEUKIN 1BETA; ISOPRENALINE; RECOMBINANT INTERLEUKIN 1BETA; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR RESPONSE; CAUSAL ATTRIBUTION; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE CONTRACTILITY; IMMUNOPATHOGENESIS; MALE; MOUSE; NONHUMAN;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIOMYOPATHIES; INTERLEUKIN-1BETA; ISOPROTERENOL; MALE; MICE; MYOCARDIAL CONTRACTION; VENTRICULAR FUNCTION, LEFT;

EID: 84879244759     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0625-0     Document Type: Article

References (18)

1. Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, Gibler WB, McCord JK, Parshall MB, Francis GS, Gheorghiade M. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation. 2010;122:1975-96.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-220.
3. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055-9.
4. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720-32.
5. Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, Shah K, Canada J, Voelkel NF, Dinarello CA, Abbate A. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7:e33438.
6. Gardin JM, Adams DB, Douglas PS, Feigenbaum H, Forst DH, Fraser AG, Grayburn PA, Katz AS, Keller AM, Kerber RE, Khandheria BK, Klein AL, Lang RM, Pierard LA, Quinones MA, Schnittger I. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr. 2002;15:275-90.
7. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993;22(4 Suppl A):61A-71A.
8. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1985;100:483-90.
9. Smith LM, McDonough KH. Inotropic sensitivity to β-adrenergic stimulation in early sepsis. Am J Physiol Heart Circ Physiol. 1988;255:H699-703.
10. Abbate A, Van Tassell BW, Biondi-Zoccai GGL. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. Biodrugs. 2012;26:217-33.
11. Liu SJ, Zhou W, Kennedy RH. Suppression of beta-adrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes. Am J Physiol. 1999;276:H141-8.
12. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci USA. 1989;86:6753-7.
13. Kumar AR, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE. Role of nitric oxide and cAMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol. 1999;276:R265-76.
14. Kan H, Finkel MS. Inflammatory mediators and reversible myocardial dysfunction. J Cell Physiol. 2003;195:1-11.
15. Garan AR, Uriel N, Sayer G, Sims D, Zahner D, Farr M, Mancini D, Jorde UP. Alteration in systemic vascular resistance and cardiac output during acute cellular rejection and recovery in heart transplant recipients. J Heart Lung Transplant. 2010;29:382-4.
16. Cooper LT. Myocarditis. N Engl J Med. 2009;360:1526-38.
17. Chockalingam A, Mehra A, Dorairajan S, Dellsperger KC. Acute left ventricular dysfunction in the critically ill. Chest. 2010;138:198-207.
18. Neil CJ, Nguyen TH, Sverdlov AL, Chirkov YY, Chong CR, Stansborough J, Beltrame JF, Kucia AM, Zeitz CJ, Frenneaux MP, Horowitz JD. Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history. Expert Rev Cardiovasc Ther. 2012;10(2):215-21.